PandemieGrippaleV1, PascalFrancis, Curation, bibRecord, 001D00

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency

Identifieur interne : 001D00 ( PascalFrancis/Curation ); précédent : 001C99; suivant : 001D01

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency

Auteurs : Surender Khurana [États-Unis] ; Lisa R. King [États-Unis] ; Jody Manischewitz [États-Unis] ; Elizabeth M. Coyle [États-Unis] ; Hana Golding [États-Unis]

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0110710

Descripteurs français

Pascal (Inist)
- Anticorps, Vaccin, Hémagglutinine, Grippe.
Wicri :
- topic : Vaccin.

English descriptors

KwdEn :
- Antibody, Hemagglutinin, Influenza, Vaccine.

Abstract

A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-binding SPR-based potency assay, which does not require any reference antisera and could be used for rapid HA quantitation and vaccine release in pandemic scenarios. The assay utilizes synthetic glycans with sialic acid (SA) of either α-2,6 or α-2,3 linkage to galactose. Only functionally active forms of HA (trimers and oligomers) recognize the SA-glycans and are quantified in this receptor-binding SPR assay. The SA-glycan SPR assay demonstrated broad dynamic range for quantitation of HA content in influenza vaccines from different manufacturers for both seasonal (A/H1N1, A/H3N2, B lineages) and pandemic influenza (A/H5N1, A/H7N9) strains with high reproducibility and low variability across multiple assays. In addition, the SA-glycan SPR assay is indicative of active HA stability, and can accurately quantify HA content in alum and oil-in-water adjuvanted influenza vaccines. Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 32`
A06				`@2 19`
A08	`01`	`1`	`ENG`	`@1 Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency`
A11	`01`	`1`		`@1 KHURANA (Surender)`
A11	`02`	`1`		`@1 KING (Lisa R.)`
A11	`03`	`1`		`@1 MANISCHEWITZ (Jody)`
A11	`04`	`1`		`@1 COYLE (Elizabeth M.)`
A11	`05`	`1`		`@1 GOLDING (Hana)`
A14	`01`			`@1 Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration @2 Bethesda, MD 20892 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 2188-2197`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000503209940090`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 40 ref.`
A47	`01`	`1`		`@0 14-0110710`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-binding SPR-based potency assay, which does not require any reference antisera and could be used for rapid HA quantitation and vaccine release in pandemic scenarios. The assay utilizes synthetic glycans with sialic acid (SA) of either α-2,6 or α-2,3 linkage to galactose. Only functionally active forms of HA (trimers and oligomers) recognize the SA-glycans and are quantified in this receptor-binding SPR assay. The SA-glycan SPR assay demonstrated broad dynamic range for quantitation of HA content in influenza vaccines from different manufacturers for both seasonal (A/H1N1, A/H3N2, B lineages) and pandemic influenza (A/H5N1, A/H7N9) strains with high reproducibility and low variability across multiple assays. In addition, the SA-glycan SPR assay is indicative of active HA stability, and can accurately quantify HA content in alum and oil-in-water adjuvanted influenza vaccines. Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay.
C02	`01`	`X`		`@0 002A05F04`
C03	`01`	`X`	`FRE`	`@0 Anticorps @5 05`
C03	`01`	`X`	`ENG`	`@0 Antibody @5 05`
C03	`01`	`X`	`SPA`	`@0 Anticuerpo @5 05`
C03	`02`	`X`	`FRE`	`@0 Vaccin @5 06`
C03	`02`	`X`	`ENG`	`@0 Vaccine @5 06`
C03	`02`	`X`	`SPA`	`@0 Vacuna @5 06`
C03	`03`	`X`	`FRE`	`@0 Hémagglutinine @5 07`
C03	`03`	`X`	`ENG`	`@0 Hemagglutinin @5 07`
C03	`03`	`X`	`SPA`	`@0 Hemoaglutinina @5 07`
C03	`04`	`X`	`FRE`	`@0 Grippe @5 14`
C03	`04`	`X`	`ENG`	`@0 Influenza @5 14`
C03	`04`	`X`	`SPA`	`@0 Gripe @5 14`
C07	`01`	`X`	`FRE`	`@0 Virose`
C07	`01`	`X`	`ENG`	`@0 Viral disease`
C07	`01`	`X`	`SPA`	`@0 Virosis`
C07	`02`	`X`	`FRE`	`@0 Infection`
C07	`02`	`X`	`ENG`	`@0 Infection`
C07	`02`	`X`	`SPA`	`@0 Infección`
N21				`@1 146`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000119

Links to Exploration step

Pascal:14-0110710

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency</title>
<author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Coyle, Elizabeth M" sort="Coyle, Elizabeth M" uniqKey="Coyle E" first="Elizabeth M." last="Coyle">Elizabeth M. Coyle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Golding, Hana" sort="Golding, Hana" uniqKey="Golding H" first="Hana" last="Golding">Hana Golding</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0110710</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0110710 INIST</idno>
<idno type="RBID">Pascal:14-0110710</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000119</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D00</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency</title>
<author><name sortKey="Khurana, Surender" sort="Khurana, Surender" uniqKey="Khurana S" first="Surender" last="Khurana">Surender Khurana</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="King, Lisa R" sort="King, Lisa R" uniqKey="King L" first="Lisa R." last="King">Lisa R. King</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Manischewitz, Jody" sort="Manischewitz, Jody" uniqKey="Manischewitz J" first="Jody" last="Manischewitz">Jody Manischewitz</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Coyle, Elizabeth M" sort="Coyle, Elizabeth M" uniqKey="Coyle E" first="Elizabeth M." last="Coyle">Elizabeth M. Coyle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
<author><name sortKey="Golding, Hana" sort="Golding, Hana" uniqKey="Golding H" first="Hana" last="Golding">Hana Golding</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibody</term>
<term>Hemagglutinin</term>
<term>Influenza</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Anticorps</term>
<term>Vaccin</term>
<term>Hémagglutinine</term>
<term>Grippe</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-binding SPR-based potency assay, which does not require any reference antisera and could be used for rapid HA quantitation and vaccine release in pandemic scenarios. The assay utilizes synthetic glycans with sialic acid (SA) of either α-2,6 or α-2,3 linkage to galactose. Only functionally active forms of HA (trimers and oligomers) recognize the SA-glycans and are quantified in this receptor-binding SPR assay. The SA-glycan SPR assay demonstrated broad dynamic range for quantitation of HA content in influenza vaccines from different manufacturers for both seasonal (A/H1N1, A/H3N2, B lineages) and pandemic influenza (A/H5N1, A/H7N9) strains with high reproducibility and low variability across multiple assays. In addition, the SA-glycan SPR assay is indicative of active HA stability, and can accurately quantify HA content in alum and oil-in-water adjuvanted influenza vaccines. Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>32</s2>
</fA05>
<fA06><s2>19</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>KHURANA (Surender)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>KING (Lisa R.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MANISCHEWITZ (Jody)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>COYLE (Elizabeth M.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>GOLDING (Hana)</s1>
</fA11>
<fA14 i1="01"><s1>Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration</s1>
<s2>Bethesda, MD 20892</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>2188-2197</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000503209940090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>40 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0110710</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A WHO workshop organized following the 2009 H1N1 pandemic recommended development of alternative influenza vaccine potency assays as high priority that could expedite the release of vaccine lots in the face of future influenza pandemics. We have developed an antibody independent, simple, high throughput receptor-binding SPR-based potency assay, which does not require any reference antisera and could be used for rapid HA quantitation and vaccine release in pandemic scenarios. The assay utilizes synthetic glycans with sialic acid (SA) of either α-2,6 or α-2,3 linkage to galactose. Only functionally active forms of HA (trimers and oligomers) recognize the SA-glycans and are quantified in this receptor-binding SPR assay. The SA-glycan SPR assay demonstrated broad dynamic range for quantitation of HA content in influenza vaccines from different manufacturers for both seasonal (A/H1N1, A/H3N2, B lineages) and pandemic influenza (A/H5N1, A/H7N9) strains with high reproducibility and low variability across multiple assays. In addition, the SA-glycan SPR assay is indicative of active HA stability, and can accurately quantify HA content in alum and oil-in-water adjuvanted influenza vaccines. Importantly, there was a good agreement between HA content determined by the SPR-based potency assay and the traditional SRID assay.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Anticorps</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Antibody</s0>
<s5>05</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Anticuerpo</s0>
<s5>05</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>06</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>06</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Hémagglutinine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Hemagglutinin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Hemoaglutinina</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Grippe</s0>
<s5>14</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Influenza</s0>
<s5>14</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Gripe</s0>
<s5>14</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fN21><s1>146</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D00 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 001D00 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0110710
   |texte=   Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency

Novel antibody-independent receptor-binding SPR-based assay for rapid measurement of influenza vaccine potency

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri